Sign In / Register
IFN-gamma: Proteins and Enzymes
IFN-gamma (Interferon-gamma) is the prototype proinflammatory cytokine and is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects. In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation. IFN-gamma dimers signal through a receptor complex of two IFN-gamma R1 and two IFN-gamma R2 subunits.
15 results for "IFN-gamma Proteins and Enzymes" in Products
Search
Application
Conjugates
Low Endotoxin
Sample Size
Citations
Reviews
IFN-gamma: Proteins and Enzymes
IFN-gamma (Interferon-gamma) is the prototype proinflammatory cytokine and is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects. In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation. IFN-gamma dimers signal through a receptor complex of two IFN-gamma R1 and two IFN-gamma R2 subunits.
15 results for "IFN-gamma Proteins and Enzymes" in Products
| Source : | E. coli |
| Accession # : | NP_032363 |
| Applications : | Bioactivity |
Analyzed by SEC-MALS
| Source : | E. coli |
| Accession # : | CAA31639 |
| Applications : | Bioactivity |
Animal-Free. Earn double rewards for reviews
| Source : | E. coli |
| Accession # : | CAA31639.1 |
| Applications : | Bioactivity |
Analyzed by SEC-MALS. Intended for preclinical researchers who may transition to GMP IFN-gamma for their clinical work
| Source : | E. coli |
| Accession # : | CAA31639.1 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | P01581 |
| Applications : | Bioactivity |
| Source : | HEK293 |
| Accession # : | NP_000610.2 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | P63310 |
| Applications : | Bioactivity |
| Source : | CHO |
| Accession # : | P24770 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | P17803 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | Q9QXX2 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | P46402 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | NP_776511 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | BAA05876 |
| Applications : | Bioactivity |
| Source : | E. coli |
| Accession # : | P42161 |
| Applications : | Bioactivity |
Potent inhibitor of IFN-gamma
| Source : | CHO |
| Accession # : | P24770 |
| Applications : | Bioactivity |
